2017

Mere days before President Donald Trump was sworn into office, when any national action could (or would) be taken on drug pricing,…

The American Board of Internal Medicine (ABIM) is providing more choice to physicians who are working to maintain their board…

2016 was the year of the price increase, as leading industry players experienced significant public outrage over what appeared to…

We have previously written about Connecticut policy that was aimed at reporting payments from pharmaceutical and device…

Two prescription drug wholesalers – AmerisourceBergen Corp. and Cardinal Health Inc. – will pay $16 million and $20 million,…

In efforts to understand the rising cost of some drugs, Patient Assistance programs, particularly independent…

Recently, the Food and Drug Administration (FDA) finalized guidance detailing its approach to assigning non-proprietary names to…

The United States Department of Health and Human Services (HHS) Office of Inspector General (OIG) recently published a report,…

We have taken an interest in the growing biosimilars market in the United States. Recently, we covered the Friends of Cancer…

As reported by Regulatory Focus, the FDA announced the “safety labeling changes” (SLC) program. It will be reportedly…